Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
U2AF1 is a splicing factor of 35 kDa that serves as the small subunit of the U2 auxiliary factor complex. It is essential for the recognition of the AG dinucleotide at the 3’ splice site during spliceosome assembly in pre-mRNA processing. Mutations in U2AF1, including the Q157R substitution, are recurrent in multiple hematologic malignancies and solid tumors, and have been shown to alter normal splicing patterns, contributing to oncogenesis and disease progression. The U2AF1 protein acts primarily through RNA-protein and protein-protein interactions that facilitate gene expression regulation. U2AF1 is a promising but challenging therapeutic target due to its ubiquitous role in normal cell physiology[1][3][9].
Drugs targeting spliceosome machinery can act by modulating splicing efficiency or correcting aberrant splicing induced by U2AF1 mutations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Splicing factor U2AF 35 kDa subunit (U2AF1).